Normal view MARC view ISBD view

ACUTE RETINAL NECROSIS AFTER ADMINISTRATION OF ADALIMUMAB, A SYSTEMIC ANTITUMOR NECROSIS FACTOR ANTIBODY. - 2018

Available online through MWHC library: 2007 - present

CONCLUSION: Physicians prescribing tumor necrosis factor alpha antagonist immunosuppressive therapy should be aware of the potential of developing acute retinal necrosis. METHODS: Case report. PURPOSE: To report a case of acute retinal necrosis in a patient on anti-tumor necrosis factor alpha immunosuppressive therapy. RESULTS: A 47-year-old man with psoriasis presented with blurred vision and floaters in the left eye 4 days after receiving his fourth dose of adalimumab, a tumor necrosis factor alpha antagonist. He was diagnosed with acute retinal necrosis and was treated with intravenous acyclovir as well as prophylactic laser barricade. Seven years later, he is 20/20 with no history of a retinal detachment.


English

ISSN: 1935-1089

Standard No.: 10.1097/ICB.0000000000000499 [doi]

Subjects--Topical Terms:
*Adalimumab/ae [Adverse Effects]
*Anti-Inflammatory Agents/ae [Adverse Effects]
*Retinal Necrosis Syndrome, Acute/ci [Chemically Induced]
Humans
Male
Middle Aged
Tumor Necrosis Factor-alpha/ai [Antagonists & Inhibitors]

Subjects--Geographic Terms:
MedStar Union Memorial Hospital

Index Terms--Occupation:
Medicine

Index Terms--Function:
Case Reports
Journal Article